

Eosinophilic Research at the Cincinnati Center for Eosinophilic Disorders (CCED)

The [Cincinnati Center for Eosinophilic Disorders](#) (CCED) is a leader in research for these often-misunderstood conditions. Our research spans all states of therapeutic development. Developing new treatments and cures is an involved process that requires significant time and investment, especially during the fundamental stages of basic research and discovery validation, which are a major priority of the CCED. The CCED has a critical role in this process, working tirelessly on each stage, and has already had a key role in the development of therapeutic strategies for eosinophilic disorders such as [eosinophilic esophagitis](#) (EoE) and hypereosinophilic syndrome (HES).

Current* Pipeline of Diagnostic and Therapeutic CCED Research

Mechanism	Target	CCED Research	Therapeutic Agent	CCED Clinical Trials	Phase of Development
Suppress inflammatory response					
<i>Systemic corticosteroids</i>	Immune system	1-3			Off-label clinical use
<i>Topical corticosteroids</i>	Local inflammation	1-3	Flovent	4, 5 and Current Trial (enrollment closed)	Off-label clinical use
			Budesonide		III
Blockade of eosinophil recruitment					
<i>Chemokine inhibition</i>	CCR3	6-33			II
<i>Chemokine inhibition</i>	CCL11 (eotaxin-1)	6, 7, 9, 11, 14, 17, 19, 22-24, 27, 28, 30, 32-74	Bertilimumab		III
<i>Cytokine inhibition</i>	IL-13	1, 3, 14, 15, 17, 24, 26, 27, 30, 31, 53, 56, 57, 59, 63, 67, 72, 75-109	QAX576	Current Trial (enrollment closed)	III
			RPC4046		
<i>Cytokine receptor inhibition</i>	IL-13R	27, 76, 78, 79, 88, 100, 102, 104, 105			III
<i>Cytokine receptor inhibition</i>	IL-4R	27, 31, 72, 75-77, 99, 100, 102, 103, 110, 111	Dupilumab	Current Trial (enrollment open)	II
<i>Chemokine inhibition</i>	CCL26 (eotaxin-3)	1, 3, 21, 26, 77, 80, 101, 112-114			Preclinical
<i>Adhesion molecule inhibition</i>	Periostin	115			Preclinical

<i>Adhesion molecule inhibition</i>	CDH26	Pre-publication			Fundamental
<i>Anti-inflammatory</i>	TGF- β	27, 69, 103, 116	Lorsartan	Current Trial (enrolling soon)	II
<i>Impaired barrier function</i>	Improve barrier function	104, 117			Fundamental
<i>Epigenome modifiers</i>	Epigenome	80			Fundamental
Inhibition of eosinophil survival					
<i>Cytokine inhibition</i>	IL-5	7, 11, 13-15, 22, 25, 26, 29-31, 38, 44, 46, 47, 49, 50, 53, 55-61, 63, 68, 70, 72, 73, 77, 102, 109, 118-140	Mepolizumab	25, 29, 126, 135	FDA-approved for eosinophilic asthma
			Reslizumab	¹³⁸ and Current Trial (enrollment closed)	FDA-approved for eosinophilic asthma
<i>Eosinophil depletion</i>	IL-5R- α		Benralizumab		III
<i>Activation of inhibitory receptor</i>	Siglec-8	122, 134, 141, 142			Preclinical
<i>Activation of inhibitory receptor</i>	PIRB	28, 143			Preclinical
Inhibition of eosinophil activation					
<i>Cytokine inhibition</i>	TSLP	144, 145	AMG 157		II
<i>Cytokine inhibition</i>	IL-33	Pre-publication			Preclinical
Molecular diagnostics					
<i>Gene expression</i>	Eosinophilic Esophagitis (EoE) Diagnostic Panel	1, 105, 107, 146-148			Clinical validation

*As of December 2015

- Blanchard C, Mingler MK, Vicario M, et al. IL-13 involvement in eosinophilic esophagitis: transcriptome analysis and reversibility with glucocorticoids. *J Allergy Clin Immunol*. Dec 2007;120(6):1292-1300.
- Furuta GT, Liacouras CA, Collins MH, et al. Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. *Gastroenterology*. Oct 2007;133(4):1342-1363.
- Caldwell JM, Blanchard C, Collins MH, et al. Glucocorticoid-regulated genes in eosinophilic esophagitis: a role for FKBP51. *J Allergy Clin Immunol*. Apr 2010;125(4):879-888 e878.
- Noel RJ, Putnam PE, Collins MH, et al. Clinical and immunopathologic effects of swallowed fluticasone for eosinophilic esophagitis. *Clin Gastroenterol Hepatol*. Jul 2004;2(7):568-575.
- Konikoff MR, Noel RJ, Blanchard C, et al. A randomized, double-blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis. *Gastroenterology*. Nov 2006;131(5):1381-1391.

6. Gao JL, Sen AI, Kitauro M, et al. Identification of a mouse eosinophil receptor for the CC chemokine eotaxin. *Biochem Biophys Res Commun*. Jun 25 1996;223(3):679-684.
7. Rothenberg ME, Ownbey R, Mehlhop PD, et al. Eotaxin triggers eosinophil-selective chemotaxis and calcium flux via a distinct receptor and induces pulmonary eosinophilia in the presence of interleukin 5 in mice. *Mol Med*. May 1996;2(3):334-348.
8. Zimmermann N, Bernstein JA, Rothenberg ME. Polymorphisms in the human CC chemokine receptor-3 gene. *Biochim Biophys Acta*. Nov 8 1998;1442(2-3):170-176.
9. Rothenberg ME. Eotaxin. An essential mediator of eosinophil trafficking into mucosal tissues. *Am J Respir Cell Mol Biol*. Sep 1999;21(3):291-295.
10. Zimmermann N, Conkright JJ, Rothenberg ME. CC chemokine receptor-3 undergoes prolonged ligand-induced internalization. *J Biol Chem*. Apr 30 1999;274(18):12611-12618.
11. Hogan SP, Mishra A, Brandt EB, Foster PS, Rothenberg ME. A critical role for eotaxin in experimental oral antigen-induced eosinophilic gastrointestinal allergy. *Proc Natl Acad Sci U S A*. Jun 6 2000;97(12):6681-6686.
12. Zimmermann N, Daugherty BL, Kavanaugh JL, El-Awar FY, Moulton EA, Rothenberg ME. Analysis of the CC chemokine receptor 3 gene reveals a complex 5' exon organization, a functional role for untranslated exon 1, and a broadly active promoter with eosinophil-selective elements. *Blood*. Oct 1 2000;96(7):2346-2354.
13. Zimmermann N, Daugherty BL, Stark JM, Rothenberg ME. Molecular analysis of CCR-3 events in eosinophilic cells. *J Immunol*. Jan 15 2000;164(2):1055-1064.
14. Foster PS, Mould AW, Yang M, et al. Elemental signals regulating eosinophil accumulation in the lung. *Immunol Rev*. Feb 2001;179:173-181.
15. Yang M, Hogan SP, Mahalingam S, et al. Eotaxin-2 and IL-5 cooperate in the lung to regulate IL-13 production and airway eosinophilia and hyperreactivity. *J Allergy Clin Immunol*. Nov 2003;112(5):935-943.
16. Zimmermann N, Rothenberg ME. Receptor internalization is required for eotaxin-induced responses in human eosinophils. *J Allergy Clin Immunol*. Jan 2003;111(1):97-105.
17. Fulkerson PC, Zimmermann N, Brandt EB, et al. Negative regulation of eosinophil recruitment to the lung by the chemokine monokine induced by IFN-gamma (Mig, CXCL9). *Proc Natl Acad Sci U S A*. Feb 17 2004;101(7):1987-1992.
18. Fulkerson PC, Zhu H, Williams DA, Zimmermann N, Rothenberg ME. CXCL9 inhibits eosinophil responses by a CCR3- and Rac2-dependent mechanism. *Blood*. Jul 15 2005;106(2):436-443.
19. Pope SM, Zimmermann N, Stringer KF, Karow ML, Rothenberg ME. The eotaxin chemokines and CCR3 are fundamental regulators of allergen-induced pulmonary eosinophilia. *J Immunol*. Oct 15 2005;175(8):5341-5350.
20. Zimmermann N, Colyer JL, Koch LE, Rothenberg ME. Analysis of the CCR3 promoter reveals a regulatory region in exon 1 that binds GATA-1. *BMC Immunol*. 2005;6:7.
21. Blanchard C, Wang N, Stringer KF, et al. Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. *J Clin Invest*. Feb 2006;116(2):536-547.
22. Dixon H, Blanchard C, Deschoolmeester ML, et al. The role of Th2 cytokines, chemokines and parasite products in eosinophil recruitment to the gastrointestinal mucosa during helminth infection. *Eur J Immunol*. Jul 2006;36(7):1753-1763.
23. Fulkerson PC, Fischetti CA, McBride ML, Hassman LM, Hogan SP, Rothenberg ME. A central regulatory role for eosinophils and the eotaxin/CCR3 axis in chronic experimental allergic airway inflammation. *Proc Natl Acad Sci U S A*. Oct 31 2006;103(44):16418-16423.
24. Fulkerson PC, Fischetti CA, Rothenberg ME. Eosinophils and CCR3 regulate interleukin-13 transgene-induced pulmonary remodeling. *Am J Pathol*. Dec 2006;169(6):2117-2126.
25. Stein ML, Collins MH, Villanueva JM, et al. Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. *J Allergy Clin Immunol*. Dec 2006;118(6):1312-1319.
26. Bullock JZ, Villanueva JM, Blanchard C, et al. Interplay of adaptive th2 immunity with eotaxin-3/c-C chemokine receptor 3 in eosinophilic esophagitis. *J Pediatr Gastroenterol Nutr*. Jul 2007;45(1):22-31.
27. Munitz A, Brandt EB, Mingler M, Finkelman FD, Rothenberg ME. Distinct roles for IL-13 and IL-4 via IL-13 receptor alpha1 and the type II IL-4 receptor in asthma pathogenesis. *Proc Natl Acad Sci U S A*. May 20 2008;105(20):7240-7245.
28. Munitz A, McBride ML, Bernstein JS, Rothenberg ME. A dual activation and inhibition role for the paired immunoglobulin-like receptor B in eosinophils. *Blood*. Jun 15 2008;111(12):5694-5703.

29. Stein ML, Villanueva JM, Buckmeier BK, et al. Anti-IL-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels. *J Allergy Clin Immunol*. Jun 2008;121(6):1473-1483, 1483 e1471-1474.
30. Rayapudi M, Mavi P, Zhu X, et al. Indoor insect allergens are potent inducers of experimental eosinophilic esophagitis in mice. *J Leukoc Biol*. Aug 2010;88(2):337-346.
31. Wen T, Besse JA, Mingler MK, Fulkerson PC, Rothenberg ME. Eosinophil adoptive transfer system to directly evaluate pulmonary eosinophil trafficking in vivo. *Proc Natl Acad Sci U S A*. Apr 9 2013;110(15):6067-6072.
32. Miyazaki D, Nakamura T, Ohbayashi M, et al. Ablation of type I hypersensitivity in experimental allergic conjunctivitis by eotaxin-1/CCR3 blockade. *Int Immunol*. Feb 2009;21(2):187-201.
33. Takeda A, Baffi JZ, Kleinman ME, et al. CCR3 is a target for age-related macular degeneration diagnosis and therapy. *Nature*. Jul 9 2009;460(7252):225-230.
34. Rothenberg ME, Luster AD, Leder P. Murine eotaxin: an eosinophil chemoattractant inducible in endothelial cells and in interleukin 4-induced tumor suppression. *Proc Natl Acad Sci U S A*. Sep 12 1995;92(19):8960-8964.
35. Rothenberg ME, Luster AD, Lilly CM, Drazen JM, Leder P. Constitutive and allergen-induced expression of eotaxin mRNA in the guinea pig lung. *J Exp Med*. Mar 1 1995;181(3):1211-1216.
36. Garcia-Zepeda EA, Rothenberg ME, Ownbey RT, Celestin J, Leder P, Luster AD. Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia. *Nat Med*. Apr 1996;2(4):449-456.
37. Garcia-Zepeda EA, Rothenberg ME, Weremowicz S, Sarafi MN, Morton CC, Luster AD. Genomic organization, complete sequence, and chromosomal location of the gene for human eotaxin (SCYA11), an eosinophil-specific CC chemokine. *Genomics*. May 1 1997;41(3):471-476.
38. Lamkhioed B, Renzi PM, Abi-Younes S, et al. Increased expression of eotaxin in bronchoalveolar lavage and airways of asthmatics contributes to the chemotaxis of eosinophils to the site of inflammation. *J Immunol*. Nov 1 1997;159(9):4593-4601.
39. Lilly CM, Nakamura H, Kesselman H, et al. Expression of eotaxin by human lung epithelial cells: induction by cytokines and inhibition by glucocorticoids. *J Clin Invest*. Apr 1 1997;99(7):1767-1773.
40. Luster AD, Rothenberg ME. Role of the monocyte chemoattractant protein and eotaxin subfamily of chemokines in allergic inflammation. *J Leukoc Biol*. Nov 1997;62(5):620-633.
41. Minshall EM, Cameron L, Lavigne F, et al. Eotaxin mRNA and protein expression in chronic sinusitis and allergen-induced nasal responses in seasonal allergic rhinitis. *Am J Respir Cell Mol Biol*. Dec 1997;17(6):683-690.
42. Rothenberg ME, MacLean JA, Pearlman E, Luster AD, Leder P. Targeted disruption of the chemokine eotaxin partially reduces antigen-induced tissue eosinophilia. *J Exp Med*. Feb 17 1997;185(4):785-790.
43. Cook EB, Stahl JL, Lilly CM, et al. Epithelial cells are a major cellular source of the chemokine eotaxin in the guinea pig lung. *Allergy Asthma Proc*. Jan-Feb 1998;19(1):15-22.
44. Hogan SP, Mould AW, Young JM, et al. Cellular and molecular regulation of eosinophil trafficking to the lung. *Immunol Cell Biol*. Oct 1998;76(5):454-460.
45. Matthews AN, Friend DS, Zimmermann N, et al. Eotaxin is required for the baseline level of tissue eosinophils. *Proc Natl Acad Sci U S A*. May 26 1998;95(11):6273-6278.
46. van de Rijn M, Mehlhop PD, Judkins A, Rothenberg ME, Luster AD, Oettgen HC. A murine model of allergic rhinitis: studies on the role of IgE in pathogenesis and analysis of the eosinophil influx elicited by allergen and eotaxin. *J Allergy Clin Immunol*. Jul 1998;102(1):65-74.
47. Mishra A, Hogan SP, Lee JJ, Foster PS, Rothenberg ME. Fundamental signals that regulate eosinophil homing to the gastrointestinal tract. *J Clin Invest*. Jun 1999;103(12):1719-1727.
48. Gouon-Evans V, Rothenberg ME, Pollard JW. Postnatal mammary gland development requires macrophages and eosinophils. *Development*. Jun 2000;127(11):2269-2282.
49. Mishra A, Hogan SP, Brandt EB, Rothenberg ME. Peyer's patch eosinophils: identification, characterization, and regulation by mucosal allergen exposure, interleukin-5, and eotaxin. *Blood*. Aug 15 2000;96(4):1538-1544.
50. Mould AW, Ramsay AJ, Matthaei KI, Young IG, Rothenberg ME, Foster PS. The effect of IL-5 and eotaxin expression in the lung on eosinophil trafficking and degranulation and the induction of bronchial hyperreactivity. *J Immunol*. Feb 15 2000;164(4):2142-2150.

51. Hogan SP, Mishra A, Brandt EB, et al. A pathological function for eotaxin and eosinophils in eosinophilic gastrointestinal inflammation. *Nat Immunol.* Apr 2001;2(4):353-360.
52. Mishra A, Weaver TE, Beck DC, Rothenberg ME. Interleukin-5-mediated allergic airway inflammation inhibits the human surfactant protein C promoter in transgenic mice. *J Biol Chem.* Mar 16 2001;276(11):8453-8459.
53. Pope SM, Brandt EB, Mishra A, et al. IL-13 induces eosinophil recruitment into the lung by an IL-5- and eotaxin-dependent mechanism. *J Allergy Clin Immunol.* Oct 2001;108(4):594-601.
54. Rothenberg ME, Mishra A, Brandt EB, Hogan SP. Gastrointestinal eosinophils in health and disease. *Adv Immunol.* 2001;78:291-328.
55. Rothenberg ME, Mishra A, Brandt EB, Hogan SP. Gastrointestinal eosinophils. *Immunol Rev.* Feb 2001;179:139-155.
56. Webb DC, McKenzie AN, Matthaei KI, Rothenberg ME, Foster PS. Distinct spatial requirement for eosinophil-induced airways hyperreactivity. *Immunol Cell Biol.* Apr 2001;79(2):165-169.
57. Yang M, Hogan SP, Henry PJ, et al. Interleukin-13 mediates airways hyperreactivity through the IL-4 receptor-alpha chain and STAT-6 independently of IL-5 and eotaxin. *Am J Respir Cell Mol Biol.* Oct 2001;25(4):522-530.
58. Hogan SP, Foster PS, Rothenberg ME. Experimental analysis of eosinophil-associated gastrointestinal diseases. *Curr Opin Allergy Clin Immunol.* Jun 2002;2(3):239-248.
59. Mattes J, Yang M, Mahalingam S, et al. Intrinsic defect in T cell production of interleukin (IL)-13 in the absence of both IL-5 and eotaxin precludes the development of eosinophilia and airways hyperreactivity in experimental asthma. *J Exp Med.* Jun 3 2002;195(11):1433-1444.
60. Mishra A, Hogan SP, Brandt EB, Rothenberg ME. IL-5 promotes eosinophil trafficking to the esophagus. *J Immunol.* Mar 1 2002;168(5):2464-2469.
61. Mishra A, Hogan SP, Brandt EB, et al. Enterocyte expression of the eotaxin and interleukin-5 transgenes induces compartmentalized dysregulation of eosinophil trafficking. *J Biol Chem.* Feb 8 2002;277(6):4406-4412.
62. Mattes J, Hulett M, Xie W, et al. Immunotherapy of cytotoxic T cell-resistant tumors by T helper 2 cells: an eotaxin and STAT6-dependent process. *J Exp Med.* Feb 3 2003;197(3):387-393.
63. Mishra A, Rothenberg ME. Intratracheal IL-13 induces eosinophilic esophagitis by an IL-5, eotaxin-1, and STAT6-dependent mechanism. *Gastroenterology.* Nov 2003;125(5):1419-1427.
64. Forbes E, Smart VE, D'Aprile A, et al. T helper-2 immunity regulates bronchial hyperresponsiveness in eosinophil-associated gastrointestinal disease in mice. *Gastroenterology.* Jul 2004;127(1):105-118.
65. Fulkerson PC, Zimmermann N, Hassman LM, Finkelman FD, Rothenberg ME. Pulmonary chemokine expression is coordinately regulated by STAT1, STAT6, and IFN-gamma. *J Immunol.* Dec 15 2004;173(12):7565-7574.
66. Hogan SP, Rothenberg ME. Review article: The eosinophil as a therapeutic target in gastrointestinal disease. *Aliment Pharmacol Ther.* Dec 2004;20(11-12):1231-1240.
67. Pope SM, Fulkerson PC, Blanchard C, et al. Identification of a cooperative mechanism involving interleukin-13 and eotaxin-2 in experimental allergic lung inflammation. *J Biol Chem.* Apr 8 2005;280(14):13952-13961.
68. Simons JE, Rothenberg ME, Lawrence RA. Eotaxin-1-regulated eosinophils have a critical role in innate immunity against experimental *Brugia malayi* infection. *Eur J Immunol.* Jan 2005;35(1):189-197.
69. Letuve S, Lajoie-Kadoch S, Audusseau S, et al. IL-17E upregulates the expression of proinflammatory cytokines in lung fibroblasts. *J Allergy Clin Immunol.* Mar 2006;117(3):590-596.
70. Simson L, Ellyard JI, Dent LA, et al. Regulation of carcinogenesis by IL-5 and CCL11: a potential role for eosinophils in tumor immune surveillance. *J Immunol.* Apr 1 2007;178(7):4222-4229.
71. Ahrens R, Waddell A, Seidu L, et al. Intestinal macrophage/epithelial cell-derived CCL11/eotaxin-1 mediates eosinophil recruitment and function in pediatric ulcerative colitis. *J Immunol.* Nov 15 2008;181(10):7390-7399.
72. Johnson TR, Rothenberg ME, Graham BS. Pulmonary eosinophilia requires interleukin-5, eotaxin-1, and CD4+ T cells in mice immunized with respiratory syncytial virus G glycoprotein. *J Leukoc Biol.* Sep 2008;84(3):748-759.
73. Munitz A, Seidu L, Cole ET, Ahrens R, Hogan SP, Rothenberg ME. Resistin-like molecule alpha decreases glucose tolerance during intestinal inflammation. *J Immunol.* Feb 15 2009;182(4):2357-2363.
74. Waddell A, Ahrens R, Steinbrecher K, et al. Colonic eosinophilic inflammation in experimental colitis is mediated by Ly6C(high) CCR2(+) inflammatory monocyte/macrophage-derived CCL11. *J Immunol.* May 15 2011;186(10):5993-6003.

75. Wan H, Kaestner KH, Ang SL, et al. Foxa2 regulates alveolarization and goblet cell hyperplasia. *Development*. Feb 2004;131(4):953-964.
76. Brandt EB, Munitz A, Orekov T, et al. Targeting IL-4/IL-13 signaling to alleviate oral allergen-induced diarrhea. *J Allergy Clin Immunol*. Jan 2009;123(1):53-58.
77. Blanchard C, Stucke EM, Rodriguez-Jimenez B, et al. A striking local esophageal cytokine expression profile in eosinophilic esophagitis. *J Allergy Clin Immunol*. Jan 2011;127(1):208-217, 217 e201-207.
78. Rothenberg ME, Wen T, Shik D, Cole ET, Mingler MM, Munitz A. IL-13 receptor alpha1 differentially regulates aeroallergen-induced lung responses. *J Immunol*. Nov 1 2011;187(9):4873-4880.
79. Wu D, Ahrens R, Osterfeld H, et al. Interleukin-13 (IL-13)/IL-13 receptor alpha1 (IL-13Ralpha1) signaling regulates intestinal epithelial cystic fibrosis transmembrane conductance regulator channel-dependent Cl⁻ secretion. *J Biol Chem*. Apr 15 2011;286(15):13357-13369.
80. Lim EJ, Lu TX, Blanchard C, Rothenberg ME. Epigenetic regulation of the IL-13-induced human eotaxin-3 gene by CREB-binding protein-mediated histone 3 acetylation. *J Biol Chem*. Apr 15 2011;286(15):13193-13204.
81. Rosa-Rosa L, Zimmermann N, Bernstein JA, Rothenberg ME, Khurana Hershey GK. The R576 IL-4 receptor alpha allele correlates with asthma severity. *J Allergy Clin Immunol*. Nov 1999;104(5):1008-1014.
82. Nikolaidis NM, Zimmermann N, King NE, et al. Trefoil factor-2 is an allergen-induced gene regulated by Th2 cytokines and STAT6 in the lung. *Am J Respir Cell Mol Biol*. Oct 2003;29(4):458-464.
83. Zimmermann N, Hershey GK, Foster PS, Rothenberg ME. Chemokines in asthma: cooperative interaction between chemokines and IL-13. *J Allergy Clin Immunol*. Feb 2003;111(2):227-242; quiz 243.
84. Zimmermann N, King NE, Laporte J, et al. Dissection of experimental asthma with DNA microarray analysis identifies arginase in asthma pathogenesis. *J Clin Invest*. Jun 2003;111(12):1863-1874.
85. King NE, Zimmermann N, Pope SM, et al. Expression and regulation of a disintegrin and metalloproteinase (ADAM) 8 in experimental asthma. *Am J Respir Cell Mol Biol*. Sep 2004;31(3):257-265.
86. Blanchard C, Mishra A, Saito-Akei H, Monk P, Anderson I, Rothenberg ME. Inhibition of human interleukin-13-induced respiratory and oesophageal inflammation by anti-human-interleukin-13 antibody (CAT-354). *Clin Exp Allergy*. Aug 2005;35(8):1096-1103.
87. Finkelman FD, Rothenberg ME, Brandt EB, Morris SC, Strait RT. Molecular mechanisms of anaphylaxis: lessons from studies with murine models. *J Allergy Clin Immunol*. Mar 2005;115(3):449-457; quiz 458.
88. Finkelman FD, Yang M, Perkins C, et al. Suppressive effect of IL-4 on IL-13-induced genes in mouse lung. *J Immunol*. Apr 15 2005;174(8):4630-4638.
89. Zimmermann N, Doepker MP, Witte DP, et al. Expression and regulation of small proline-rich protein 2 in allergic inflammation. *Am J Respir Cell Mol Biol*. May 2005;32(5):428-435.
90. Brandt EB, Scribner TA, Akei HS, Rothenberg ME. Experimental gastrointestinal allergy enhances pulmonary responses to specific and unrelated allergens. *J Allergy Clin Immunol*. Aug 2006;118(2):420-427.
91. Fulkerson PC, Fischetti CA, Hassman LM, Nikolaidis NM, Rothenberg ME. Persistent effects induced by IL-13 in the lung. *Am J Respir Cell Mol Biol*. Sep 2006;35(3):337-346.
92. Yang M, Rangasamy D, Matthaei KI, et al. Inhibition of arginase I activity by RNA interference attenuates IL-13-induced airways hyperresponsiveness. *J Immunol*. Oct 15 2006;177(8):5595-5603.
93. McGraw DW, Elwing JM, Fogel KM, et al. Crosstalk between Gi and Gq/Gs pathways in airway smooth muscle regulates bronchial contractility and relaxation. *J Clin Invest*. May 2007;117(5):1391-1398.
94. Mishra A, Wang M, Schlotman J, et al. Resistin-like molecule-beta is an allergen-induced cytokine with inflammatory and remodeling activity in the murine lung. *Am J Physiol Lung Cell Mol Physiol*. Aug 2007;293(2):L305-313.
95. Munitz A, Bachelet I, Finkelman FD, Rothenberg ME, Levi-Schaffer F. CD48 is critically involved in allergic eosinophilic airway inflammation. *Am J Respir Crit Care Med*. May 1 2007;175(9):911-918.
96. Brandt EB, Mingler MK, Stevenson MD, et al. Surfactant protein D alters allergic lung responses in mice and human subjects. *J Allergy Clin Immunol*. May 2008;121(5):1140-1147 e1142.
97. Herbert DR, Orekov T, Perkins C, Rothenberg ME, Finkelman FD. IL-4R alpha expression by bone marrow-derived cells is necessary and sufficient for host protection against acute schistosomiasis. *J Immunol*. Apr 1 2008;180(7):4948-4955.
98. Rothenberg ME. 2007 E. Mead Johnson award: scientific pursuit of the allergy problem. *Pediatr Res*. Jul 2008;64(1):110-115.

99. Herbert DR, Yang JQ, Hogan SP, et al. Intestinal epithelial cell secretion of RELM-beta protects against gastrointestinal worm infection. *J Exp Med*. Dec 21 2009;206(13):2947-2957.
100. Lu TX, Munitz A, Rothenberg ME. MicroRNA-21 is up-regulated in allergic airway inflammation and regulates IL-12p35 expression. *J Immunol*. Apr 15 2009;182(8):4994-5002.
101. Blanchard C, Stucke EM, Burwinkel K, et al. Coordinate interaction between IL-13 and epithelial differentiation cluster genes in eosinophilic esophagitis. *J Immunol*. Apr 1 2010;184(7):4033-4041.
102. Finkelman FD, Hogan SP, Hershey GK, Rothenberg ME, Wills-Karp M. Importance of cytokines in murine allergic airway disease and human asthma. *J Immunol*. Feb 15 2010;184(4):1663-1674.
103. Herbert DR, Orekov T, Roloson A, et al. Arginase I suppresses IL-12/IL-23p40-driven intestinal inflammation during acute schistosomiasis. *J Immunol*. Jun 1 2010;184(11):6438-6446.
104. Sivaprasad U, Warriar MR, Gibson AM, et al. IL-13Ralpha2 has a protective role in a mouse model of cutaneous inflammation. *J Immunol*. Dec 1 2010;185(11):6802-6808.
105. Zuo L, Fulkerson PC, Finkelman FD, et al. IL-13 induces esophageal remodeling and gene expression by an eosinophil-independent, IL-13R alpha 2-inhibited pathway. *J Immunol*. Jul 1 2010;185(1):660-669.
106. Sherrill JD, Rothenberg ME. Genetic dissection of eosinophilic esophagitis provides insight into disease pathogenesis and treatment strategies. *J Allergy Clin Immunol*. Jul 2011;128(1):23-32; quiz 33-24.
107. Lu TX, Lim EJ, Wen T, et al. MiR-375 is downregulated in epithelial cells after IL-13 stimulation and regulates an IL-13-induced epithelial transcriptome. *Mucosal Immunol*. Jul 2012;5(4):388-396.
108. Munitz A, Cole ET, Karo-Atar D, Finkelman FD, Rothenberg ME. Resistin-like molecule-alpha regulates IL-13-induced chemokine production but not allergen-induced airway responses. *Am J Respir Cell Mol Biol*. May 2012;46(5):703-713.
109. Collison A, Hatchwell L, Verrills N, et al. The E3 ubiquitin ligase midline 1 promotes allergen and rhinovirus-induced asthma by inhibiting protein phosphatase 2A activity. *Nat Med*. Feb 2013;19(2):232-237.
110. Baye TM, Butsch Kovacic M, Biagini Myers JM, et al. Differences in candidate gene association between European ancestry and African American asthmatic children. *PLoS One*. 2011;6(2):e16522.
111. Niese KA, Chiamonte MG, Ellies LG, Rothenberg ME, Zimmermann N. The cationic amino acid transporter 2 is induced in inflammatory lung models and regulates lung fibrosis. *Respir Res*. 2010;11:87.
112. Blanchard C, Wang N, Rothenberg ME. Eosinophilic esophagitis: pathogenesis, genetics, and therapy. *J Allergy Clin Immunol*. Nov 2006;118(5):1054-1059.
113. Konikoff MR, Blanchard C, Kirby C, et al. Potential of blood eosinophils, eosinophil-derived neurotoxin, and eotaxin-3 as biomarkers of eosinophilic esophagitis. *Clin Gastroenterol Hepatol*. Nov 2006;4(11):1328-1336.
114. Rothenberg ME. Biology and treatment of eosinophilic esophagitis. *Gastroenterology*. Oct 2009;137(4):1238-1249.
115. Blanchard C, Mingler MK, McBride M, et al. Periostin facilitates eosinophil tissue infiltration in allergic lung and esophageal responses. *Mucosal Immunol*. Jul 2008;1(4):289-296.
116. Abonia JP, Franciosi JP, Rothenberg ME. TGF-beta1: Mediator of a feedback loop in eosinophilic esophagitis--or should we really say mastocytic esophagitis? *J Allergy Clin Immunol*. Dec 2010;126(6):1205-1207.
117. Hogan SP, Seidu L, Blanchard C, et al. Resistin-like molecule beta regulates innate colonic function: barrier integrity and inflammation susceptibility. *J Allergy Clin Immunol*. Jul 2006;118(1):257-268.
118. Owen WF, Rothenberg ME, Petersen J, et al. Interleukin 5 and phenotypically altered eosinophils in the blood of patients with the idiopathic hypereosinophilic syndrome. *J Exp Med*. Jul 1 1989;170(1):343-348.
119. Rothenberg ME, Petersen J, Stevens RL, et al. IL-5-dependent conversion of normodense human eosinophils to the hypodense phenotype uses 3T3 fibroblasts for enhanced viability, accelerated hypodensity, and sustained antibody-dependent cytotoxicity. *J Immunol*. Oct 1 1989;143(7):2311-2316.
120. Post TW, Bozic CR, Rothenberg ME, Luster AD, Gerard N, Gerard C. Molecular characterization of two murine eosinophil beta chemokine receptors. *J Immunol*. Dec 1 1995;155(11):5299-5305.
121. Mishra A, Hogan SP, Brandt EB, Rothenberg ME. An etiological role for aeroallergens and eosinophils in experimental esophagitis. *J Clin Invest*. Jan 2001;107(1):83-90.

122. Aizawa H, Zimmermann N, Carrigan PE, Lee JJ, Rothenberg ME, Bochner BS. Molecular analysis of human Siglec-8 orthologs relevant to mouse eosinophils: identification of mouse orthologs of Siglec-5 (mSiglec-F) and Siglec-10 (mSiglec-G). *Genomics*. Nov 2003;82(5):521-530.
123. Khaldoyanidi S, Sikora L, Broide DH, Rothenberg ME, Sriramarao P. Constitutive overexpression of IL-5 induces extramedullary hematopoiesis in the spleen. *Blood*. Feb 1 2003;101(3):863-868.
124. Garrett JK, Jameson SC, Thomson B, et al. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. *J Allergy Clin Immunol*. Jan 2004;113(1):115-119.
125. Rothenberg ME. Eosinophilic gastrointestinal disorders (EGID). *J Allergy Clin Immunol*. Jan 2004;113(1):11-28; quiz 29.
126. Stein ML, Rothenberg ME. Hypereosinophilic syndromes and new therapeutic approaches including anti-IL-5. *Expert Rev Clin Immunol*. Nov 2005;1(4):633-644.
127. Sutton SA, Assa'ad AH, Rothenberg ME. Anti-IL-5 and hypereosinophilic syndromes. *Clin Immunol*. Apr 2005;115(1):51-60.
128. Brandt EB, Zimmermann N, Muntel EE, et al. The alpha4bbeta7-integrin is dynamically expressed on murine eosinophils and involved in eosinophil trafficking to the intestine. *Clin Exp Allergy*. Apr 2006;36(4):543-553.
129. Rothenberg ME, Hogan SP. The eosinophil. *Annu Rev Immunol*. 2006;24:147-174.
130. Yamada Y, Rothenberg ME, Lee AW, et al. The FIP1L1-PDGFRalpha fusion gene cooperates with IL-5 to induce murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)-like disease. *Blood*. May 15 2006;107(10):4071-4079.
131. Fulkerson PC, Rothenberg ME. Origin, regulation and physiological function of intestinal eosinophils. *Best Pract Res Clin Gastroenterol*. 2008;22(3):411-423.
132. Mishra A, Wang M, Pemmaraju VR, et al. Esophageal remodeling develops as a consequence of tissue specific IL-5-induced eosinophilia. *Gastroenterology*. Jan 2008;134(1):204-214.
133. Yamada Y, Sanchez-Aguilera A, Brandt EB, et al. FIP1L1/PDGFRalpha synergizes with SCF to induce systemic mastocytosis in a murine model of chronic eosinophilic leukemia/hypereosinophilic syndrome. *Blood*. Sep 15 2008;112(6):2500-2507.
134. Zimmermann N, McBride ML, Yamada Y, et al. Siglec-F antibody administration to mice selectively reduces blood and tissue eosinophils. *Allergy*. Sep 2008;63(9):1156-1163.
135. Ogbogu PU, Bochner BS, Butterfield JH, et al. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. *J Allergy Clin Immunol*. Dec 2009;124(6):1319-1325 e1313.
136. Rosenwasser LJ, Rothenberg ME. IL-5 pathway inhibition in the treatment of asthma and Churg-Strauss syndrome. *J Allergy Clin Immunol*. Jun 2010;125(6):1245-1246.
137. Lacy P, Willetts L, Kim JD, et al. Agonist activation of f-actin-mediated eosinophil shape change and mediator release is dependent on Rac2. *Int Arch Allergy Immunol*. May 16 2011;156(2):137-147.
138. Spergel JM, Rothenberg ME, Collins MH, et al. Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. *J Allergy Clin Immunol*. Feb 2012;129(2):456-463, 463 e451-453.
139. Lu TX, Lim EJ, Itskovich S, et al. Targeted ablation of miR-21 decreases murine eosinophil progenitor cell growth. *PLoS One*. 2013;8(3):e59397.
140. Roufosse FE, Kahn JE, Gleich GJ, et al. Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes. *J Allergy Clin Immunol*. Feb 2013;131(2):461-467 e461-465.
141. Gao PS, Shimizu K, Grant AV, et al. Polymorphisms in the sialic acid-binding immunoglobulin-like lectin-8 (Siglec-8) gene are associated with susceptibility to asthma. *Eur J Hum Genet*. Jun 2010;18(6):713-719.
142. Wen T, Mingler MK, Blanchard C, Wahl B, Pabst O, Rothenberg ME. The pan-B cell marker CD22 is expressed on gastrointestinal eosinophils and negatively regulates tissue eosinophilia. *J Immunol*. Feb 1 2012;188(3):1075-1082.
143. Munitz A, Cole ET, Beichler A, et al. Paired immunoglobulin-like receptor B (PIR-B) negatively regulates macrophage activation in experimental colitis. *Gastroenterology*. Aug 2010;139(2):530-541.
144. Rothenberg ME, Spergel JM, Sherrill JD, et al. Common variants at 5q22 associate with pediatric eosinophilic esophagitis. *Nat Genet*. Apr 2010;42(4):289-291.
145. Sherrill JD, Gao PS, Stucke EM, et al. Variants of thymic stromal lymphopoietin and its receptor associate with eosinophilic esophagitis. *J Allergy Clin Immunol*. Jul 2010;126(1):160-165 e163.
146. Abonia JP, Blanchard C, Butz BB, et al. Involvement of mast cells in eosinophilic esophagitis. *J Allergy Clin Immunol*. Jul 2010;126(1):140-149.

147. Lu TX, Hartner J, Lim EJ, et al. MicroRNA-21 limits in vivo immune response-mediated activation of the IL-12/IFN-gamma pathway, Th1 polarization, and the severity of delayed-type hypersensitivity. *J Immunol*. Sep 15 2011;187(6):3362-3373.
148. Lu TX, Sherrill JD, Wen T, et al. MicroRNA signature in patients with eosinophilic esophagitis, reversibility with glucocorticoids, and assessment as disease biomarkers. *J Allergy Clin Immunol*. Apr 2012;129(4):1064-1075 e1069.